The Medicines Company to Host Investor Conference Call & Webcast During National Lipid Association’s 2019 Scientific Sessions
May 10 2019 - 7:00AM
Business Wire
- Company management and clinical trial
investigators will review interim results on the long-term safety
and efficacy data of inclisiran from ongoing ORION-3 study
The Medicines Company (NASDAQ:MDCO) will host a conference call
and webcast for investors on Saturday, May 18, 2019, at 5:30 p.m.
EDT. During the call, the Company’s management and clinical trial
investigators will review interim results on the long-term safety
and efficacy data of inclisiran from the ongoing ORION-3 study. The
data will be presented during the late-breaking clinical trial
session earlier the same day at the National Lipid Association
(NLA) 2019 Scientific Sessions in Miami.
Inclisiran, the first cholesterol-lowering therapy in the small
interfering RNA (siRNA) class, is the only medicine in late-stage
clinical development with the potential to deliver potent, durable
and consistent lowering of LDL cholesterol through twice-a-year
dosing.
ORION-3 is an open-label Phase 2, extension study (of ORION-1)
to assess the efficacy, safety and tolerability of long-term dosing
of inclisiran. The study also evaluates safety and efficacy of
switching patients treated with evolocumab to inclisiran. Follow up
for this latter group is still ongoing and will be presented at a
later date.
Conference Call
The conference call may be accessed as follows:
U.S./Canada: (877) 407-0312
International: (201) 389-0899
Conference ID: 13690839
The slide deck and live webcast may be accessed in the Investors
section of The Medicines Company website.
A taped replay of the conference call will be available for
approximately one month. The replay may be accessed as follows:
U.S./Canada: (877) 660-6853
International: (201) 612-7415
Conference ID: 13690839
A replay of the webcast will also be available in the Investors
section of The Medicines Company website.
About The Medicines Company
The Medicines Company is a biopharmaceutical company whose
purpose is to halt the deadly progression of atherosclerosis and
the cardiovascular risk created by high levels of LDL-C, or bad
cholesterol. Our team is focused on transformational solutions that
address the daily challenges that patients, physicians and payers
confront in cardiovascular care. The Company is headquartered in
Parsippany, New Jersey. For more information, please visit
www.themedicinescompany.com and follow us on Twitter @MDCONews and
LinkedIn.
About Inclisiran
Inclisiran is a small interfering RNA (siRNA) therapy being
studied to evaluate its ability to lower low-density lipoprotein
(LDL) cholesterol – also known as LDL-C or bad cholesterol.
Inclisiran is designed to prevent the production of proprotein
convertase subtilisin/kexin type 9 (PCSK9) at its source in the
liver. Inclisiran is not yet approved for use by the FDA or any
other regulatory authority. The Medicines Company obtained global
rights to develop, manufacture and commercialize inclisiran under a
license and collaboration agreement with Alnylam
Pharmaceuticals.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190510005011/en/
Investor RelationsKrishna Gorti, M.D.Vice President,
Investor Relations973 290 6122krishna.gorti@themedco.com
Media InquiriesMichael BlashVice President,
Communications973 290 6100michael.blash@themedco.com
Medicines (NASDAQ:MDCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicines (NASDAQ:MDCO)
Historical Stock Chart
From Apr 2023 to Apr 2024